News

Find out about our current activities

Click on the headlines below to learn more about the latest happenings at InSphero.  You can also view recent Media Releases or register for our 3D InSight™ Newsletter to keep informed of recent InSphero news.  

ADA Presentations Highlight Superior Functionality of InSphero Standardized Islet Microtissues for Diabetes Drug Screening

ADA Presentations Highlight Superior Functionality of InSphero Standardized Islet Microtissues for Diabetes Drug Screening

ETH Zurich researchers present single-islet study using novel microfluidic setup to display in vivo-like temporal insulin response to high glucose. PDF Version

Schlieren, Switzerland -  June 19, 2017  InSphero AG highlighted unique advantages of its physiologically relevant 3D InSight™ Islet Microtissue Platform to drive more efficient development of anti-diabetic drugs at the American Diabetes Association 77th Scientific Sessions in San Diego, CA. Also, a pioneering study describing a microfluidic single islet perifusion platform, developed by researchers at the ETH Zurich, was presented during open and moderated poster sessions held during the conference.

Dr. Burcak Yesildag, islet product manager at InSphero and presenter of the study at ADA says, “Loss of first phase, reduction in the second phase and impairment of the oscillatory pattern of insulin secretion are characteristic features of type 2 diabetes. Therefore, study of dynamic insulin release with in vitro perifusion assays is a crucial component of pancreatic islet research. However, inherent heterogeneity in islet size and composition necessitates pooling of multiple islets for each experimental condition, which entails inefficient use of donor material and decreased experimental resolution due to uncoordinated inter-islet function.”

InSphero 3D InSight™ Islet Microtissues - uniform in size, cellular composition and function – were combined with a novel microfluidic system engineered by Dr. Andreas Hierlemann’s research group at the Swiss Federal Institute of Technology (ETH). The microfluidic system facilitates rapid glucose switches and short sampling intervals, making it possible to study dynamic insulin secretion at the single-islet level in vitro.

Says Yesildag, “ETH observed an organotypic biphasic and pulsatile secretion of insulin from our islet microtissues which was physiologically modulated by various insulin secretagogues. The results very closely mirrored the magnitude and frequency of the response seen in humans. This collaboration provides further evidence that the in vivo-like functionality of our islet model makes it a powerful new tool for islet researchers to help accelerate anti-diabetic drug development.”

3D InSight™ Islet Microtissues are a standardized primary islet model developed by InSphero that display organotypic function with an average 13-fold increase in glucose-stimulated insulin secretion (GSIS) for at least 28 days in culture.

For more information about InSphero 3D InSight™ Islet Microtissues, visit www.insphero.com or watch the video.

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Patrick Guye
Chief Scientific Officer
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Its robust and highly physiologically relevant suite of 3D InSight™ Microtissues and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues driven solely by cellular self-assembly. The company specializes in delivering assay-ready and custom 3D models derived from liver, pancreas, and tumor tissues, to provide unrivalled biological insight into liver toxicology, metabolic diseases (e.g., diabetes and liver diseases), and oncology (with a focus on immuno-oncology). All InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized platform, ready for research. Field application scientists and research staff with expertise in working with 3D models help ensure efficient integration and onsite training as needed. For customers who prefer an outsourcing strategy with fast turnaround, InSphero also offers contract research services utilizing their 3D microtissue models.

InSphero 3D InSight™ solutions drive significant findings in peer-reviewed journals, through collaborative industry initiatives such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn.

 

Images

Islet no background        Logo ohne Tagline ISGreen RGB

InSphero 3D InSight™ Islet Microtissues help drug discovery and development groups identify more effective drugs for diabetes by providing more relevant and reliable 3-dimensional cell based models for in vitro efficacy testing.

InSphero, AstraZeneca Islet Microtissue Work Wins Best Poster Award at EASD Islet Study Group

InSphero, AstraZeneca Islet Microtissue Work Awarded "Best Poster" at EASD Islet Study Group & Beta Cell Workshop

Schlieren, Switzerland - May 9, 2017

InSphero's Burcak Yesildag, PhD and collaborators at AstraZeneca Mölndal were announced on Tuesday, May 9th as winners of the Poster Award at the annual EASD Islet Study Group & Beta Cell Workshop, held in Dresden, Germany.  The poster, entitled "A Novel Standardized In Vitro Islet Model System for Assessment of Pancreatic β-cell Proliferation" is the second such honor for InSphero in 2017, having received the ELRIG Research & Innovation "Best Technology" Award in March for the full portfolio of advanced 3D InSight™ Microtissues for drug safety and efficacy testing.

The scientific program at the annual conference covers a wide spectrum of topics in the field of islet biology, including beta cell development, maturation and regeneration, beta cell function, genetics & epigenetics of beta cells, beta cell therapy and beta cell interaction with immune cells. Attendees include leaders in the field, rising stars as well as postdocs and students, who come together to exchange their latest findings and ideas in order to foster progress and networking in the field of islet biology.  

In addition to May presentations at the European Society for Animal Cell Technology (ESACT) in Lausanne, Switzerland and the Midwest Islet Club (Madison, WI) featuring 3D InSight™ Islet Microtissues, Dr. Yesildag will present groundbreaking work performed in collaboration with the ETH Zurich assessing islet microtissue function under perifusion conditions in a microphyisiological system (MPS) at the 77th Scientific Sessions of the American Diabetes Association (ADA) Meeting held June 9-13 in San Diego, CA.  

 

BYe

Dr. Burcak Yesildag, InSphero AG 

Islet no background

InSphero 3D InSight™ Islet Microtissues provide greater confidence to pharmaceutical drug discovery and development groups in their efforts to better assess diabetes drug efficacy and safety.

InSphero Announces Collaboration with NIH National Center for Advancing Translational Sciences (NCATS)

InSphero Announces Collaboration with NIH National Center for Advancing Translational Sciences (NCATS)

Joint study will accelerate development of physiologically relevant 3D models for anti-cancer drug screening.  PDF Version

 

Schlieren, Switzerland -  May 03, 2017  InSphero AG today announced a collaboration with the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to identify anti-cancer agents with cytotoxic activity in 3D tumor models. In this joint project, NCATS will use patient-derived xenograft (PDX) tumor microtissues, provided by InSphero in its 384 well platform, to screen a library of anti-cancer agents for anti-tumor efficacy using assays that measure cell proliferation, tissue integrity, and tissue size.

“For cancer drug discovery, it is of critical importance to have models that are physiologically relevant,” says InSphero Chief Technology Officer and Co-founder Jens M. Kelm, Ph.D. “3D microtissues models provide a more accurate reflection of the tumor and its extracellular environment.” The latest generation of customizable 3D tumor microtissue models available from InSphero also capture the heterogeneity of tumor cell populations, making them ideal for investigating special tumor cell sub-populations called cancer stem cells (CSCs) or tumor-initiating cells. These cells have self-renewal potential and are thought to drive tumor formation and metastasis. CSCs appear to be resistant to current chemotherapy and radiation-therapy treatments that produce cancer recurrence, thus there is a heightened interest among oncologists to be able to screen therapeutic agents that target CSCs and other tumor cell sub-populations.

“To unlock the full potential of more physiologically relevant models to fosterfor drug development we need to be able to integrate 3D cancer models into the drug screening process as early as possible,” says Dr. Kelm. InSphero will work closely with researchers at NCATS to evaluate how PDX-derived tumor microtissues can be applied in primary and secondary screening campaigns using small to mid-size compound libraries.

“Our project with InSphero is yet another example of how NCATS fosters collaborations to explore novel technologies that carry the promise to accelerate discovery of molecular therapeutic agents across multiple disease areas,” says Anton Simeonov, Ph.D., acting deputy scientific director of NCATS’ Division of Pre-Clinical Innovation.

For more information about NCATS, visit https://ncats.nih.gov.

For more information about InSphero, visit www.insphero.com

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Patrick Guye
Chief Scientific Officer
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumors. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn.

Image

insphero logo


News Archive

 

Company video

company-video-inspheor